Attgeno is a pharmaceutical company based in Stockholm, Sweden.

The company is developing a novel nitric oxide donor called Supernitro for the treatment of acute pulmonary hypertension caused by cardiovascular or pulmonary diseases. Supernitro will be the first and only intravenous drug to selectively treat acute high blood pressure in the lungs

Year of investment
2018

Sector
Drug development

Location
Stockholm, Sweden

Website
https://attgeno.com/